Cytokinetics sued Bristol Myers Squibb to invalidate a patent on Camzyos, claiming it unfairly targets its rival heart drug Myqorzo (aficamten).
Cytokinetics and Bristol Myers Squibb are fierce market rivals. Now they’re also rivals in court.
Cytokinetics filed a lawsuit against Bristol Myers
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
It's BMS vs. Celgene investors once more after US appeals court revives lawsuit
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
Appeals court revives $6.7B lawsuit against Bristol Myers Squibb
Cytokinetics executives said their first FDA-approved drug is off to a strong start as it goes up against its Bristol Myers…
Myqorzo’s success in “non-obstructive” hypertrophic cardiomyopathy separates it from Bristol Myers Squibb’s rival Camzyos and…
A Cytokinetics heart disease drug — already approved in one indication — succeeded in another Phase 3 trial, a potential boost…
The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug…
Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over…
